Investors

Investors arrow News Releases
Print E-mail
News Releases

All Releases  
View Summary Peregrine Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2010 Financial Results
Jul 14, 2010
PDF 20.0 KB Add to Briefcase
View Summary Peregrine Initiates Second Randomized Phase IIb Lung Cancer Trial Using First-In-Class PS-Targeting Monoclonal Antibody Bavituximab
Jul 14, 2010
PDF 12.2 KB Add to Briefcase
View Summary Peregrine to Report Fourth Quarter and Fiscal Year 2010 Financial Results After Market on July 14, 2010
Jun 30, 2010
PDF 7.7 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Joins Russell 3000 Index
Jun 28, 2010
PDF 8.3 KB Add to Briefcase
View Summary Peregrine Provides Update on Government-Sponsored Research Program
Jun 28, 2010
PDF 10.1 KB Add to Briefcase
View Summary Peregrine Set to Join Russell 3000
Jun 14, 2010
PDF 8.8 KB Add to Briefcase
View Summary Peregrine to Highlight Key Clinical Data From Four ASCO Presentations at Needham Healthcare Conference
Jun 9, 2010
PDF 13.3 KB Add to Briefcase
View Summary Positive Phase II Lung Cancer Data to Be Presented at ASCO Support Recently Opened Registrational Phase IIb Trial for Bavituximab
Jun 4, 2010
PDF 12.3 KB Add to Briefcase
View Summary Glioblastoma Multiforme Data From Peregrine's Novel Brain Cancer Therapy Cotara(R) to Be Reported at ASCO
Jun 3, 2010
PDF 13.0 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals to Present at the Needham & Company Ninth Annual Healthcare Conference
Jun 2, 2010
PDF 6.8 KB Add to Briefcase
View Summary New Progression-Free Survival Data From Peregrine's Bavituximab in Phase II Refractory Breast Cancer Trial to Be Presented at ASCO
May 28, 2010
PDF 11.9 KB Add to Briefcase
View Summary Phase II Advanced Breast Cancer Data to Be Presented at ASCO Highlight Promising Tumor Response and Progression-Free Survival Data With Peregrine's Bavituximab
May 27, 2010
PDF 11.7 KB Add to Briefcase
View Summary Peregrine to Present Lung, Advanced Breast, and Brain Cancer Clinical Data at 2010 ASCO Annual Meeting
May 20, 2010
PDF 11.6 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals to Present at the Rodman & Renshaw Sixth Annual Global Investment Conference
May 10, 2010
PDF 7.7 KB Add to Briefcase
View Summary Avid Bioservices to Highlight Integrated Commercial Manufacturing Capabilities at 2010 BIO International Convention
May 3, 2010
PDF 7.4 KB Add to Briefcase
View Summary Peregrine and Stason Enter Into Agreement for Innovative Tumor Necrosis Therapy (TNT) Technologies
May 3, 2010
PDF 13.5 KB Add to Briefcase
View Summary Three Presentations at AACR Annual Meeting Show Breadth of Applications for Peregrine's Innovative Phospholipid-Targeting Technologies
Apr 21, 2010
PDF 14.9 KB Add to Briefcase
View Summary New Preclinical Breast Cancer Study Shows Peregrine's PS-Targeting Antibodies Can Reverse Tumor-Induced Immune Suppression
Apr 19, 2010
PDF 12.4 KB Add to Briefcase
View Summary New Study Shows Combining Peregrine's Bavituximab With an Apoptosis-Inducing Agent Can Eradicate Tumors in a Model of Advanced Breast Cancer
Apr 15, 2010
PDF 11.5 KB Add to Briefcase
View Summary Peregrine Announces Data From Four Clinical Studies Will Be Presented at 2010 ASCO Annual Meeting
Apr 13, 2010
PDF 7.9 KB Add to Briefcase
Showing 1-20 of 396 Page: 1 2 3 ... 20  Next 20
= add release to Briefcase
Stock Information  
NASDAQ:PPHM
$1.62   - 0.05
Jul 30, 2010
4:00 PM ET
Quotes delayed at least 20 minutes. Information provided by eSignal.
Shareholder Tools  

Shareholder Materials  
To sign up for electronic delivery of shareholder materials click here
 
 
© 2003/2010 Peregrine Pharmaceuticals Inc., All Rights Reserved   Disclaimer | Safe Harbor